Genetic interleukin-6 receptor blockade, Chronic Disease Risk and Longevity. Results from the Women's Health Initiative.

Stephanie Wissel, Kathleen M Hovey, Chris A Andrews, Connor R Miller, Aladdin H Shadyab, Robert B Wallace, Su Yon Jung, Rami Nassir, Charles Eaton, Marcia Stefanick, Andrea LaCroix, JoAnn E Manson, Sylvia Wassertheil-Smoller, Michael J LaMonte, Bernhard Haring

Department of Medicine I, University of Würzburg, Bavaria, Germany.Department of Medicine I, University of Würzburg, Bavaria, Germany. · pubmed

Paper

Abstract

Interleukin-6 (IL-6) levels have been related to increased risk of chronic disease and mortality. Whether genetic IL-6 receptor (IL6R) blockade is associated with lower chronic disease risk or greater longevity is unknown.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that genetic IL-6 receptor blockade is associated with lower chronic disease risk and potentially greater longevity. This research addresses a genetic mechanism that could influence aging and longevity, making it relevant to the field.

Author of this paper? Send a correction.